Sergio Martínez‐Yélamos

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 173 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +5

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

M. Alba Mañé-Martínez, Bob Olsson, Laura Bau et al. · Multiple Sclerosis Journal · 2015 · 161 citations · Full text

Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis

Juan Mañá, Manuel Rubio‐Rivas, N Martínez Villalba et al. · Medicine · 2017 · 135 citations · Full text

Consecutive Patients, Spontaneous Remission, Clinical Finding +15

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

María Sepúlveda, Marta Aldea, Domingo Escudero et al. · Multiple Sclerosis Journal · 2017 · 98 citations